Remember meForgot password?
    Log in with Twitter
Blog In Health

Mislabelled drugs

By Tim Sandle
Posted Aug 14, 2012 in Health
The FDA’s Medwatch service has update its list of mislabelled drugs and other medical devices, as a warning to consumers.
The following drugs required modifications:
Avinza (morphine sulfate) Extended-Release Capsules
Butrans (buprenorphine) Transdermal System
Dantrium (dantrolene sodium) Oral Capsule
Dolophine (methadone hydrochloride) Tablets
Duragesic (Fentanyl Transdermal System)
Embeda (morphine sulfate and naltrexone hydrochloride) Extended-Release Capsules
Exalgo (hydromorphone HCl) Extended-Release Tablets
Kadian (morphine sulfate) Extended-Release Capsules
Methadone hydrochloride Oral Solution and Concentrate
MS Contin (Morphine Sulfate Controlled-Release) Tablets
Nucynta ER (tapentadol) Extended-Release Oral Tablets
Opana ER (oxymorphone hydrochloride) Extended-Release Tablets
Oxycontin (oxycodone hydrochloride controlled-release) Tablets
Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
AzaSite (azithromycin ophthalmic solution)
Biaxin (clarithromycin)
Diovan (valsartan) Tablets and Diovan HCT (valsartan/hydrochlorothiazide)
Caduet (amlodipine/atorvastatin) Tablets
Eraxis (anidulafungin) Powder for Injection
Mirapex (pramipexole dihydrochloride)
Natrecor (nesiritide) for Injection
Prograf (tacrolimus) Capsules and Injection
Sanctura (trospium chloride)
Strattera (atomoxetine hydrochloride) capsules
Zinecard (dexrazoxane) for injection
For further details, see the FDA.

More about Drugs, Pharmaceutical
Latest News
Top News